The LEADER Trial: Liraglutide's Cardiovascular Evidence
TRIAL-000005
Part of the DietApp.com GLP-1 Trial Database, a comprehensive, regularly reviewed resource.
What It Is
LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results, is the clinical trial that established liraglutide's approval for reducing cardiovascular risk in adults with type 2 diabetes. It enrolled 9,340 participants (4,668 on liraglutide, 4,672 on placebo) with type 2 diabetes at high cardiovascular risk, with a median follow-up of 3.8 years, one of the longer-duration major GLP-1 trials.
Key Results
LEADER demonstrated a reduction in major adverse cardiovascular events with liraglutide compared to placebo, forming the evidence base for Victoza's cardiovascular risk reduction indication. Post-hoc analyses of LEADER data have also identified kidney-protective effects, including slower decline in kidney function among participants with reduced baseline kidney function.
Why This Trial Still Matters
LEADER is one of the foundational cardiovascular outcome trials in the GLP-1 class, predating and informing the design of later trials like SUSTAIN-6 and SELECT. Mediation analyses of LEADER data have helped researchers understand which factors, blood sugar control, blood pressure, and others, actually drive the cardiovascular benefit seen with liraglutide.
References
- PMC: Effects of Liraglutide and Semaglutide on Cardiovascular and Renal Outcomes, LEADER and SUSTAIN 6
- Circulation: Effect of Semaglutide and Liraglutide on Kidney Outcomes, Pooled Analysis of SUSTAIN 6 and LEADER
Related Resources
Related Articles
LEADER's Role in the Broader GLP-1 Cardiovascular Evidence Base
| Trial | Medication | Duration | Real Result |
|---|---|---|---|
| LEADER | Liraglutide | 3.8 years | Real MACE reduction, one of the longest GLP-1 trials |
| SUSTAIN-6 | Semaglutide | 2.1 years | Real MACE reduction, informed by LEADER's design |
See DietApp's SUSTAIN-6 trial page, which LEADER's design directly informed, and SELECT for how this evidence later extended to a non-diabetes population.
Frequently Asked Questions
Why was LEADER's follow-up period so much longer than other trials? A real, deliberate design choice to capture cardiovascular outcomes with greater statistical confidence.
Does LEADER's kidney finding apply to everyone on liraglutide? The kidney-protective signal was specifically identified in participants with reduced baseline kidney function, not a universal finding.
How did LEADER shape later trials? Its design and findings directly informed how SUSTAIN-6 was structured, a real, documented influence on the field.
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Download DietApp.com to track your own progress alongside the evidence behind your treatment.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
Last medically reviewed and updated: July 11, 2026.
leader-trial-liraglutide